GSK
GSK
903 hedge funds and large institutions have $12.7B invested in GSK in 2024 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 306 increasing their positions, 321 reducing their positions, and 69 closing their positions.
93% more call options, than puts
Call options by funds: $200M | Put options by funds: $104M
32% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 69
2% more funds holding
Funds holding: 887 → 903 (+16)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0.11% less ownership
Funds ownership: 15.29% → 15.19% (-0.11%)
5% less repeat investments, than reductions
Existing positions increased: 306 | Existing positions reduced: 321
8% less capital inflows, than outflows
Capital inflows: $922M | Capital outflows: $1B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$131M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$96.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$91M |
| 4 |
Millennium Management
New York
|
+$56.6M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$52.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$230M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$110M |
| 3 |
Morgan Stanley
New York
|
-$88.1M |
| 4 |
LMR Partners
London,
United Kingdom
|
-$53.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$41M |
GSK Hedge Fund Activity: Q3 2024 in Review
903 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2024, worth a combined $12.7B — up 5.7% from $12B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new GSK positions and 69 closed out — a net gain of 22 holders — while 306 added to existing stakes and 321 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $131M. The largest seller was Holocene Advisors, cutting an estimated $230M.
- 903 institutional investors held GSK (GSK) as of Q3 2024, up from 887 in Q2 2024.
- Funds reported $12.7B of GSK stock for Q3 2024, up 5.7% quarter-over-quarter.
- 91 funds opened new GSK positions in Q3 2024 and 69 closed out, a net change of +22 holders.
- The largest GSK buyer in Q3 2024 was Goldman Sachs, an estimated $131M added.
- The largest GSK seller in Q3 2024 was Holocene Advisors, an estimated $230M sold.
Based on aggregated 13F filings for Q3 2024.